Navigation Links
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Date:11/6/2007

- Data confirms safety and HbA1c reductions seen in ischemic patients with

diabetes in earlier clinical trials -

ORLANDO, Fla., Nov. 6 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that data from a prospectively identified analysis of 2,220 diabetic patients from the MERLIN TIMI-36 study showed that Ranexa(R) (ranolazine extended-release tablets) significantly reduced hemoglobin A1c (HbA1c), increased the number of patients achieving the clinical HbA1c treatment target of 7.0 percent or less and reduced the incidence of newly increased HbA1c in patients without diabetes at baseline.

The findings were presented today at the American Heart Association Scientific Sessions in Orlando, Florida by Dr. David Morrow of the TIMI Study Group.

In patients with diabetes treated with Ranexa in the study, at four months HbA1c had declined approximately 0.7 percentage points, from a starting mean baseline of 7.5 to 6.8 percent, and 0.43 percentage points compared to placebo (p<0.001). Patients taking Ranexa were significantly more likely (p<0.001) to achieve the HbA1c treatment target of less than 7.0 percent, with 59 percent of diabetic patients on Ranexa achieving this target at four months.

Patients without diabetes at baseline who received Ranexa had a 32 percent reduction (p=0.003) in their risk of newly diagnosed hyperglycemia (as defined by having an HbA1c of greater than 6.0 percent or a new fasting glucose of more than 110mg/dL). Worsening hyperglycemia (defined as greater than a one percent increase in HbA1c) was 37 percent less likely (p<0.001) in the Ranexa treated group and no increased hypoglycemia or weight gain were observed in Ranexa patient
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... June 25, 2015 Research and Markets( ... Market by Technology, Imaging and by Application - Forecast to 2020" ... market is expected to reach $13.1 Billion in 2020 from an ... The market is dominated by North America ... Asia , and Rest of the World (RoW). The cancer ...
(Date:7/2/2015)... Pharma Major Lupin Limited today announced the acquisition of ... subject to certain closing conditions. The acquisition marks ... 765 billion in sales, placing it as one of the ... Health). For over a decade, Russian pharmaceutical market recorded double ... Russia to be one of the ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/8mfjxh/2015_new ) has announced the addition of ... Chemistry and Immunodiagnostics: Global Challenges, Emerging Technologies, ... 2015 New Frontiers in Clinical ... Competitive Landscape is a new seven-country strategic ...
Breaking Medicine Technology:Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
... Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data ... 1 trial show that afatinib (BIBW 2992) reached a ... in progression-free survival (PFS) in advanced non-small cell lung ... growth factor receptor (EGFR) mutation.(1)  The updated LUX-Lung 1 ...
... Clarient, Inc. (Nasdaq: CLRT ), a ... the pharmaceutical industry, today announced the commercial launch of ... the likelihood of recurrence of breast cancer following surgery ... an optimal set of five biomarkers that are able ...
Cached Medicine Technology:New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 2New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 3New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 4New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 5Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test 2Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test 3Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test 4
(Date:7/2/2015)... ... ... summer in full swing, Americans are flocking to Canada’s many lakes to reel in their ... the world, and it’s easy to understand why. From the Pacific Northwest Coast of British ... fishing is a huge industry, and Americans make up the vast majority of anglers from ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... “ LIFX ... the latest and coolest technology products available to consumers. Amanda Forstrom, a technology expert ... light bulbs are the most versatile smart light bulbs on the market. , According ...
(Date:7/2/2015)... PEACHTREE CITY, GA (PRWEB) , ... July 02, ... ... or field sporting the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the ... physicians, fitness experts and athletic trainers. Their significant popularity has inspired four new, ...
(Date:7/2/2015)... ... July 02, 2015 , ... Six months ahead of his ... walk to raise awareness and money for the Pulmonary Hypertension Association (PHA). Stevenson ... PHA’s headquarters near Washington, D.C. by mid-September. He left Glasgow, Mont. yesterday morning and ...
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ActiveBunch.com ... a passion for social fitness. Built to function as a lifestyle community, Active Bunch ... them the opportunity to network, meet, and participate in discussions or group events. ...
Breaking Medicine News(10 mins):Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2
... To tackle obesity in school children, and inculcate the practice ... in the// school curriculum was put forward, which has received ... announcing this piece of good news, Union minister A Ramadoss ... diabetes. We are at present identifying teachers who would take ...
... the University of Illinois at Chicago have taken the ... congestive heart failure.// ,A new formula ... physicians prescribe the proper amount of the powerful heart ... heart to work efficiently, strengthening the force of the ...
... results, a study of more than 1,200 patients with extremely ... of California, San Diego (UCSD) School of// Medicine showed that ... on gender. ,“Sex is like a prism that ... and women,” said Daniel T. O’Connor, M.D., UCSD professor of ...
... have breast symptoms, including enlarged or painful breast tissue, ... researchers from Mayo Clinic Cancer Center. // Mammograms are ... which are very rare in males. ,Their study, ... the San Antonio Breast Cancer Symposium, suggests physicians should ...
... more African countries will be included in the $1.2 billion ... this program has risen to 23. // This five-year program ... eradication of malaria. ,More than a million people ... are from Africa, most of them being children. ...
... doorsteps is becoming a sunrise industry in the national capital ... - where food plays a defining part. // ... leading a healthier life. Awareness towards organic food is growing. ... Navdanya, a leading organic food products company., ,"People in ...
Cached Medicine News:Health News:Researchers Devise Safer Way to Dose Lifesaving Heart Drug 2Health News:Surprising Interaction Between Genes, Gender, and Hypertension 2Health News:Surprising Interaction Between Genes, Gender, and Hypertension 3Health News:Use of Mammograms in Men 2Health News:Organic Food Fever Catches Up In Delhi 2Health News:Organic Food Fever Catches Up In Delhi 3
... The Bard Kugel hernia patch in ... polypropylene. This construction creates a positioning pocket, ... into proper placement. The patch also contains ... ring allows the patch to spring open ...
... is a sterile, pre-shaped, three-dimensional device constructed ... mesh cylinder to a circular underlay patch.,The ... and innovative design combines the three most ... the repair of inguinal hernias. ,Its Onlay ...
Surgisis Inguinal Hernia Matrix is implanted to reinforce soft tissues in the inguinal floor to repair inguinal hernias. Supplied sterile in peel-open packages. Intended for one-time use....
... newest addition to Laserscopes family of multi-application ... choose from, 1064nm Nd:YAG and 532nm KTP, ... non-invasive aesthetic laser market by pushing the ... maintaining the safety and reliability record of ...
Medicine Products: